Pelvic Organ Prolapse (POP) is one of the most common conditions women face worldwide, but the solutions are not equitably accessible. Patients living with POP are navigating symptoms like bleeding and urinary incontinence, which are very personal, sensitive issues affecting their everyday lives. This constant state of concern places a psychological toll on patients and creates anxiety around ready-access to ongoing care and treatment support. For affected women, this uncertainty translates into a heavy burden - emotional, cultural, and financial. Many women may also be hesitant to engage with healthcare providers due to previous disempowering or culturally unsafe experiences. The health system, in turn, absorbs the consequences: sub-optimal treatment outcomes, avoidable issues when treatment regimens are not adhered to, and strain on already stretched clinical resources. This combination of access inequity and system inefficiency leads to poorer health outcomes and reinforces intergenerational disadvantage, particularly for Māori and Pasifika women.

Pelvic Organ Prolapse (POP) is a common condition affecting women globally, yet access to effective care remains unequal. Symptoms like bleeding and urinary incontinence can significantly impact daily life and wellbeing. Limited access to care, alongside disempowering or culturally unsafe experiences, creates emotional, cultural, and financial burdens—particularly for Māori and Pasifika women—and contributes to poorer health outcomes. E-Leviate addresses this gap with a pessary device that provides structural support and targeted oestrogen delivery. By reducing the need for frequent clinical visits and improving treatment adherence, it supports better outcomes while empowering patients and whānau to take greater control of their health.

People living with POP (often older women) and their whānau. Māori and Pasifika women are more likely to present later and are overrepresented in hospital admissions, despite POP not being more prevalent in these communities.

Scale: Number of POP patients using the E-Leviate device.

Depth: Fewer adverse events from pessary failure and/or poor adherence; fewer clinical visits required; improved day-to-day condition management.

Duration: Benefits accrue across the treatment period, often long-term.

E-Leviate fills a key gap in POP care: while pessaries are commonly used, no existing solution offers both structural support and targeted oestregen delivery. By simplifying care and reducing reliance on frequent appointments, it can improve outcomes and make it easier for priority communities to access and sustain treatment—especially where clinical access is constrained.

Evidence risk: Limited access to patient-level data (and it may not be ethical to obtain) constrains direct measurement of outcomes; impact may rely on trial insights and established research, requiring extrapolation.